July 20th, Dr. Li Ming, CEO of ZSHK, was elected as the vice chairman of the third Innovation the Third Innovation and R&D Service Committee of PhIRDA. He also proposed constructive suggestions for the future work plan and development direction of the committee.

July 27th to 29th, during the 2023 Shenzhen International Biomedical Industry Innovation and Development Conference, the official launch of six major new infrastructure platforms in the biological industry, including Anling (Shenzhen), was announced. General Manager Jin Yi attended the launch ceremony and delivered a keynote speech.

August 8th, the Hong Kong Institute of Science & Innovation, Chinese Academy of Sciences visited Anling (Shenzhen) for exchanges, engaging in in-depth discussions with Dr. Li Ming, CEO of ZSHK, and various department heads of Anling (Shenzhen), on project cooperation and promotion of biomedical cooperation between Hong Kong and Shenzhen.

August 2023, Dr. Li Ming, CEO of ZSHK, has been invited to serve as a resident advisor for the University of Macau's Innovation and Entrepreneurship Center, contributing to the establishment of a technology transfer and innovation entrepreneurship ecosystem at the University of Macau.

September 13th to 16th, ZSHK Attended in BIOHK2023 and set up an exhibition booth to establish contacts and exchange ideas with experts and colleagues from various fields.

September 21st to 23rd, Anling (Shenzhen) hosted the 2023 Chinese Society of Toxicology for Toxicology Research Quality Assurance Annual Conference and the 5th China Quality Assurance Academic Conference, which was highly praised by the participating experts and scholars.

September 25th, ZSHK participated in the 8th China Biomed Innovation and Investment Conference.

October 16th to 19th , the General Manager of Anling (Shenzhen), Jin Yi, was invited to attend the 2023 Academic Conference on Reproductive Toxicology Pharmacology Theory and Technology and Scientific Product Research and Development, and delivered a special invited speech.

October 26th, Mr. Ma Jun Yi, the Public Affairs Director of ZSHK, was invited to attend the first "Tongxin Forum" of the Ping Shan District in 2023. The attendees discussed the positioning of Ping Shan in the construction of the Guangdong-Hong Kong-Macao Greater Bay Area, Ping Shan and Hong Kong's linkage, and the promotion of the development of the biomedical industry in the Greater Bay Area.

October 28th, Dr. Li Ming, CEO of ZSHK, was invited to attend the 5th International Summit on Innovative Drug Discovery at the School of Chinese Medicine of Hong Kong Baptist University, and delivered a keynote speech.

November 2023, Anling (Suzhou)was recognized as a national high-tech enterprise and named as a postdoctoral preparatory station in Suzhou High-tech Zone.

November 2023, Guangxi Bomai Biomed obtained the "Experimental Animal Use License" issued by the Autonomous Region Department of Science and Technology.

November 29th to December 2nd, ZSHK Laboratories Limited wholly-owned subsidiary Anling Biomed was invited to attend the 2023 Annual Meeting of Pharmacology and Toxicology, where General Manager Jin Yi delivered a keynote speech. The exhibition booth at the meeting received extensive attention and praise from industry customers and high-end talents.

December 7th to 8th, Anling (Shenzhen) attended the 2023 InnoXBio, with an exhibition booth at the scene, facilitating effective communication and the establishment of friendly contacts with industry colleagues.